Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
We describe a case of post-kala-azar dermal leishmaniasis occurring after diagnosis of visceral leishmaniasis in an HIV-1-infected woman. The skin lesions did not recover after treatment with oral miltefosine at 100 mg/day for five cycles of 28 days but responded to treatment with liposomal amphotericin B.
Guffanti
Monica
M
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy. guffanti.monica@hsr.it
Gaiera
Giovanni
G
Bossolasco
Simona
S
Ceserani
Norberto
N
Ratti
Deborah
D
Cinque
Paola
P
Salmaso
Flavia
F
Gianotti
Nicola
N
Lazzarin
Adriano
A
D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D000284:Administration, Oral; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015497:HIV-1; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000150:complications* / Q000188:drug therapy; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000188:drug therapy; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000977:Antiparasitic Agents; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B